# Minimally Invasive Embolization Offers Lasting Relief for Knee Osteoarthritis Pain Dissolving microspheres target abnormal blood vessels, presenting an alternative to surgery. - **Source:** [Latest Science News -- ScienceDaily](https://brifing.si/source/0eef8637-6c5b-4e79-8f5b-6c9c6b36cf16) - **Published:** 2026-10-14 - **Topic:** [Business](https://brifing.si/c/business) - **Original article:** - **On Brifing:** https://brifing.si/s/0d949945-c3dd-4d3f-87b7-3e9eaae592fe ## Filling the Arthritis Treatment Gap Over 365 million adults globally suffer from knee osteoarthritis, facing limited options when conservative treatments fail. Physical therapy, oral medications, and joint injections often lose efficacy over time. While total joint replacement is an established alternative, many patients remain medically ineligible or actively seek to delay invasive surgical interventions. ## Targeting Synovial Hypervascularity Genicular artery embolization targets abnormal hypervascularity surrounding the inflamed synovium rather than repairing damaged cartilage. Proliferating microvessels foster chronic inflammation and stimulate local sensory nerve growth. Superselective embolization interrupts this neurovascular pathway by delivering particles through a microcatheter directly into pathological arteries while preserving normal circulation. ## Deploying Dissolving Microspheres The Charité study utilized rapidly resorbable, gelatin-based microspheres engineered to dissolve completely within hours. This material combines the precise delivery of permanent particles with the reduced ischemic risk of temporary agents. Researchers hypothesize that temporary vessel occlusion sufficiently resets the local neurovascular environment to provide sustained clinical relief. ## Evaluating Real-World Cohort Data The prospective single-center trial enrolled 194 patients, comprising 114 women and 80 men with a median age of 69. All participants experienced chronic pain despite three months of conservative care. Clinicians performed 239 fluoroscopy-guided procedures between July and November 2024, including bilateral treatments for 45 patients. ## Demonstrating Technical Safety All 239 embolization procedures achieved complete technical success with zero moderate or severe adverse events recorded. Mild, self-limiting complications occurred in 6.7% of cases, primarily presenting as transient skin discoloration and one superficial puncture-site hematoma. These findings reinforce the favorable safety profile of temporary gelatin-based embolization agents. ## Tracking Sustained Pain Reduction Median Numeric Rating Scale pain scores dropped from 7 at baseline to 4 at six weeks post-procedure. Pain further declined to a median score of 3 at six months and remained stable through month twelve. The study retained high participant compliance, concluding with 79% retention at final evaluation. ## Improving Mobility and Function Standardized Knee Injury and Osteoarthritis Outcome Scores demonstrated broad functional recovery across all five measured categories. Daily living scores climbed from 53 to 71.5, while sports and recreation metrics jumped from 15 to 36. Overall quality-of-life scores more than doubled, increasing from 19 to 40 points. ## Achieving Meaningful Clinical Thresholds Eighty percent of participants who completed the one-year follow-up exceeded the minimum clinically important difference for pain relief. This benchmark requires at least a two-point reduction on the pain scale and a ten-point functional score gain. These metrics confirm that observed improvements translated into noticeable daily functional benefits. ## Analyzing Conflicting Controlled Trials While observational data remains favorable, randomized sham-controlled trials present mixed outcomes regarding mechanical efficacy. An April 2026 European Radiology study observed similar pain reductions in both embolization and sham groups, without MRI-proven inflammation decreases. Meta-analyses of multiple trials similarly found low certainty regarding specific vessel-blocking advantages over placebos. ## Navigating Structural Disease Limits Embolization does not reverse cartilage deterioration or repair mechanical joint degeneration. The Charité trial could not verify whether reducing synovial inflammation halts underlying disease progression. Consequently, clinical guidelines position the procedure as a symptom-management bridge rather than a curative therapy for advanced structural knee joint damage. ## Establishing Clinical Practice Guidance The Society of Interventional Radiology supports offering the procedure to selected patients with refractory symptoms who cannot undergo surgery. Expanding adoption requires dedicated interventional radiology training, rigorous patient screening, and large sham-controlled trials. These ongoing investigations will determine optimal particle selection and establish long-term clinical durability. ## Sources covering this story - https://www.sciencedaily.com/releases/2026/10/261013234801.htm — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._